AstraZeneca inks $800M buyout of French biotech to snag phase 3 rare disease drug
14 Mar 2024
Phase 3Drug ApprovalAcquisition
Preview
Source: FierceBiotech
Amolyt Pharma’s phase 3 study is assessing whether eneboparatide can free patients from the need to take supplements.
AstraZeneca is paying $800 million to expand into rare endocrinology, snagging itself a phase 3 candidate through the acquisition of French biotech Amolyt Pharma. The deal features $250 million in milestones tied to a regulatory event.
Buying Amolyt will give AstraZeneca control of eneboparatide, a PTHR1 agonistPTHR1 agonist that the biotech moved into phase 3 in June. Eneboparatide is designed to produce sustained and stable levels of calcium, which falls to low levels in patients with hypoparathyroidism, while preventing kidney disease and restoring bone turnover.
People with the thyroid disease take supplements to restore blood calcium levels, often for life. Amolyt’s phase 3 study is assessing whether eneboparatide can free patients from the need to take vitamin D and oral calcium. If the molecule can give patients that freedom and keep serum calcium in the normal range, the study could meet its primary endpoint and position AstraZeneca to file for approval.
Marc Dunoyer, CEO of AstraZeneca’s rare disease unit Alexion, said in a statement that eneboparatide has the “potential to lessen the often debilitating impact of low parathyroid hormone and avoid the risks of high-dose calcium supplementation.” AstraZeneca’s move to address that need is part of a push into a new therapeutic area.
“Chronic hypoparathyroid patients face a significant need for an alternative to current supportive therapies, which do not address the underlying hormone deficiency,” Dunoyer said. “We believe this program, together with Amolyt’s talented team, expertise and earlier pipeline, will enable our expansion into rare endocrinology.”
The FDA approved NPS Pharmaceuticals’ Natpara, which is now sold by Takeda, in hypoparathyroidism in 2015, but manufacturing problems have blighted the product. Takeda recalled batches from the U.S. in 2019 and, after the timeline for returning to the market slipped, decided to give up altogether in 2022. The drugmaker plans to stop manufacturing the drug globally by the end of the year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.